INCYTE CORPORATION Interest Expense Nonoperating
INCYTE CORPORATION (INCY) reported Interest Expense Nonoperating of $569.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-28.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-04-28
- INCYTE CORPORATION interest expense nonoperating for the quarter ending 2026-03-31 was $569.00K, a 13.79% decline year-over-year.
- INCYTE CORPORATION interest expense nonoperating for the quarter ending 2025-12-31 was $582.00K, a 38.90% increase year-over-year.
- INCYTE CORPORATION interest expense nonoperating for the quarter ending 2025-09-30 was $592.00K, a 23.51% decline year-over-year.
- INCYTE CORPORATION interest expense nonoperating for the quarter ending 2025-06-30 was $594.00K, a 9.59% decline year-over-year.
- INCYTE CORPORATION interest expense nonoperating for fiscal 2025 was $2.43M, a 6.49% increase from fiscal 2024.
- INCYTE CORPORATION interest expense nonoperating for fiscal 2024 was $2.28M, a 10.62% decline from fiscal 2023.
- INCYTE CORPORATION interest expense nonoperating for fiscal 2023 was $2.55M, a 4.31% decline from fiscal 2022.
- INCYTE CORPORATION interest expense nonoperating for fiscal 2022 was $2.67M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-03-31 | $569.00K 10-Q · filed 2026-04-28 | $1.15M derived: sum of 2 quarters · filed 2026-04-28 | $1.74M derived: sum of 3 quarters · filed 2026-04-28 | $2.34M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | $582.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $1.17M derived: sum of 2 quarters · filed 2026-02-10 | $1.77M derived: sum of 3 quarters · filed 2026-02-10 | $2.43M 10-K · filed 2026-02-10 |
| 2025-09-30 | $592.00K 10-Q · filed 2025-10-28 | $1.19M derived: sum of 2 quarters · filed 2025-10-28 | $1.85M 10-Q · filed 2025-10-28 | $2.27M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-06-30 | $594.00K 10-Q · filed 2025-07-29 | $1.25M 10-Q · filed 2025-07-29 | $1.67M derived: sum of 3 quarters · filed 2026-04-28 | $2.45M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-03-31 | $660.00K 10-Q · filed 2026-04-28 | $1.08M derived: sum of 2 quarters · filed 2026-04-28 | $1.85M derived: sum of 3 quarters · filed 2026-04-28 | $2.51M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $419.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $1.19M derived: sum of 2 quarters · filed 2026-02-10 | $1.85M derived: sum of 3 quarters · filed 2026-02-10 | $2.28M 10-K · filed 2026-02-10 |
| 2024-09-30 | $774.00K 10-Q · filed 2025-10-28 | $1.43M derived: sum of 2 quarters · filed 2025-10-28 | $1.86M 10-Q · filed 2025-10-28 | $2.67M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $657.00K 10-Q · filed 2025-07-29 | $1.09M 10-Q · filed 2025-07-29 | $1.89M derived: sum of 3 quarters · filed 2026-02-10 | $2.51M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $430.00K 10-Q · filed 2025-04-29 | $1.23M derived: sum of 2 quarters · filed 2026-02-10 | $1.86M derived: sum of 3 quarters · filed 2026-02-10 | $2.51M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $804.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $1.43M derived: sum of 2 quarters · filed 2026-02-10 | $2.08M derived: sum of 3 quarters · filed 2026-02-10 | $2.55M 10-K · filed 2026-02-10 |
| 2023-09-30 | $623.00K 10-Q · filed 2024-10-29 | $1.28M derived: sum of 2 quarters · filed 2024-10-29 | $1.75M 10-Q · filed 2024-10-29 | |
| 2023-06-30 | $655.00K 10-Q · filed 2024-07-30 | $1.12M 10-Q · filed 2024-07-30 | ||
| 2022-12-31 | $2.67M 10-K · filed 2025-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |